JP2019518788A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518788A5
JP2019518788A5 JP2019511816A JP2019511816A JP2019518788A5 JP 2019518788 A5 JP2019518788 A5 JP 2019518788A5 JP 2019511816 A JP2019511816 A JP 2019511816A JP 2019511816 A JP2019511816 A JP 2019511816A JP 2019518788 A5 JP2019518788 A5 JP 2019518788A5
Authority
JP
Japan
Prior art keywords
protein
protein according
seq
sequence
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518788A (ja
JP6997767B2 (ja
Filing date
Publication date
Priority claimed from GBGB1608197.8A external-priority patent/GB201608197D0/en
Application filed filed Critical
Publication of JP2019518788A publication Critical patent/JP2019518788A/ja
Publication of JP2019518788A5 publication Critical patent/JP2019518788A5/ja
Application granted granted Critical
Publication of JP6997767B2 publication Critical patent/JP6997767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511816A 2016-05-10 2017-05-10 Cd200変異体及びその使用 Active JP6997767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (3)

Publication Number Publication Date
JP2019518788A JP2019518788A (ja) 2019-07-04
JP2019518788A5 true JP2019518788A5 (enExample) 2020-06-25
JP6997767B2 JP6997767B2 (ja) 2022-03-04

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511816A Active JP6997767B2 (ja) 2016-05-10 2017-05-10 Cd200変異体及びその使用

Country Status (16)

Country Link
US (1) US11203628B2 (enExample)
EP (1) EP3455247A1 (enExample)
JP (1) JP6997767B2 (enExample)
KR (2) KR102498901B1 (enExample)
CN (1) CN109219614B (enExample)
AU (1) AU2017264825B2 (enExample)
BR (1) BR112018073280A2 (enExample)
CA (1) CA3023601A1 (enExample)
EA (1) EA201892554A1 (enExample)
GB (1) GB201608197D0 (enExample)
IL (1) IL262846B2 (enExample)
MX (1) MX386295B (enExample)
NZ (1) NZ747665A (enExample)
SG (1) SG11201809677XA (enExample)
WO (1) WO2017194941A1 (enExample)
ZA (1) ZA201807079B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
CN119522234A (zh) * 2022-05-06 2025-02-25 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
CN119365483A (zh) * 2022-05-06 2025-01-24 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4584447B2 (ja) * 1997-11-07 2010-11-24 トリリアム・セラピューティクス・インコーポレイテッド 免疫調節のための方法および組成物
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
JP2002541210A (ja) * 1999-04-13 2002-12-03 シェーリング コーポレイション 哺乳動物ox2タンパク質および関連試薬の新規な使用
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
ATE406385T1 (de) * 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
EP2500352A1 (en) * 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2121015A4 (en) * 2007-01-11 2010-03-24 Boehringer Ingelheim Int CD200 AND RECEPTOR THEREFOR, CD200R AND BONE MASS MODULATION BY ESTEOKLASTENDIFFERENZIERUNG
ES2543166T3 (es) * 2009-03-31 2015-08-17 University Of Washington Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana
KR20130005264A (ko) * 2010-01-11 2013-01-15 알렉시온 파마슈티칼스, 인코포레이티드 항-cd200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Similar Documents

Publication Publication Date Title
JP2019518788A5 (enExample)
Liang et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination
Shaik et al. Structural basis of coreceptor recognition by HIV-1 envelope spike
Carfı́ et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA
Ishimoto et al. Structural basis of CXC chemokine receptor 1 ligand binding and activation
JP5761831B2 (ja) 癌及び慢性感染の治療のための作動薬活性を有するil−2由来のポリペプチド
JP2021500855A5 (enExample)
JP2019522465A5 (enExample)
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
RU2015142999A (ru) Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения
JP2010529860A5 (enExample)
JP2017537926A5 (enExample)
JP2013519721A5 (enExample)
JP2015212284A5 (enExample)
JP2019535268A5 (ja) アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
IL294059A (en) Mutant rsv f protein and its use
JP2014510519A5 (enExample)
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
Dong et al. Structural and functional insights into the juxtamembranous amino‐terminal tail and extracellular loop regions of class B GPCRs
Holub Small scaffolds, big potential: Developing miniature proteins as therapeutic agents
JP2018508571A5 (enExample)
CN106478797B (zh) 源自于sage1的肿瘤抗原短肽
Sette et al. A shared MHC supertype motif emerges by convergent evolution in macaques and mice, but is totally absent in human MHC molecules
CN116375880A (zh) 融合蛋白及其制备方法和应用
Strosberg et al. G-protein-coupled receptor signalling through protein networks